Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Recasts Keytruda Regulatory Strategy In Head & Neck Cancer To Capitalize On KEYNOTE-048

Executive Summary

Withdrawal of sBLA for full approval of Keytruda in second-line SCCHN makes way for Merck to file for first-line use. 

Advertisement

Related Content

Global Device Approvals Snapshot: 11-17 June 2019
Keeping Track: Approvals For Polivy, Keytruda, FDA Applause For Biosimilars
US FDA Approval Actions To Watch Out For In June
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel